Several studies have investigated whether NPM1-mutated MRD monitoring during follow-up of AML patients in CR after the end of intensive treatments could foresee hematologic relapse [31,33,34,35,37,38,39,40,44,47,52,54,61,65]. This evidence concerns the gene NPM1 and acute myeloid leukemia.